Missed a GLP-1 Microdose? Late-Dose Windows, Long Breaks, and Restarting Without the Nausea

Weekly injections are easy to forget. A trip, a stomach bug, a late refill or a pen left in the office fridge is enough to push a GLP-1 microdose past its usual day, and the instinct is either to panic or to double up the following week.

This article sets out what the official prescribing information for Ozempic, Wegovy and Zepbound says about a missed GLP-1 dose, why those rules follow from each drug's half-life, and what the STEP 4 and SURMOUNT-4 trials show about longer breaks. One limit applies throughout: these rules were written for labeled doses. No study has tested missed-dose or restart rules at the sub-label doses used in microdosing protocols, so the labels are the best available guide rather than a tested microdose answer.

What should you do if you miss a GLP-1 microdose?

If you miss a GLP-1 microdose, first count the days since your usual injection day, then check the rule for your specific drug. Every weekly GLP-1 label answers the same two questions: how late can a missed dose still be taken, and how close together can two doses be. The answers differ by drug.

The Ozempic prescribing information says to take a missed dose as soon as possible within 5 days. If more than 5 days have passed, the missed dose is skipped and the next dose is taken on the regularly scheduled day. The Zepbound prescribing information uses the same structure with a shorter window: within 4 days (96 hours), otherwise skip.

In both cases the regular weekly schedule then continues as before. Nothing in either label suggests taking the skipped dose later, adding it to the next one, or shifting the whole schedule to make up for it.

How does the Wegovy missed-dose rule work?

The Wegovy rule counts forward to the next dose instead of backward from the missed one. According to the Wegovy prescribing information, if one injection is missed and the next scheduled dose is more than 2 days (48 hours) away, the missed dose is taken as soon as possible. If the next dose is less than 2 days away, the missed dose is skipped and dosing resumes on the regular day.

Wegovy now also comes as a once-daily tablet, and the tablet rule is simpler still. A missed Wegovy tablet is skipped, and the next tablet is taken the following day. Two tablets are never taken on the same day.

Wegovy is the only one of the three labels with an explicit instruction for longer gaps. If 2 or more consecutive injections are missed, the label says to restart dose escalation at a lower dose to reduce the risk of gastrointestinal side effects. The patient information puts it more plainly: after missing doses for 2 or more consecutive weeks, contact your healthcare provider about how to restart.

Can you double up or take two doses close together?

No. All three labels set a minimum gap between two doses, and none allows doubling up. The Ozempic label requires at least 2 days (more than 48 hours) between doses when the injection day is changed. The Zepbound label requires at least 3 days (72 hours) and states plainly that two doses should not be taken within 3 days of each other. Wegovy's skip rule produces the same 2-day floor.

The same gap rule is what makes it possible to move an injection day on purpose, for travel or a new work rota. Shifting a day is fine as long as the gap is respected. Our article on weekly versus split GLP-1 microdose schedules covers how dosing frequency interacts with these intervals.

Why do the late-dose windows differ between semaglutide and tirzepatide?

The labels do not say why the windows differ, but the two drugs do leave the body at different speeds. The Wegovy label gives semaglutide an elimination half-life of approximately 1 week and says the drug is present in the circulation for about 5 to 7 weeks after the last dose. The Ozempic label gives about 5 weeks. The Zepbound label gives tirzepatide an elimination half-life of approximately 5 to 6 days.

A long half-life is why a missed GLP-1 dose rarely feels like falling off a cliff. Drug levels drift down over the missed week rather than vanishing, which is also why some people notice appetite returning a few days late rather than on the missed day itself. A shorter half-life gives a little less room, which fits Zepbound's 4-day window against Ozempic's 5.

The labels do not explain how each window was chosen, so this link between half-life and window length is a reasonable reading rather than a stated rule. The windows also apply to the branded products. Compounded or research-labeled versions used in some microdose protocols have no label of their own, and their missed-dose behaviour has not been studied.

Why does restarting after a long break bring back nausea?

Restarting after a long break brings back nausea because gastrointestinal side effects cluster around dose increases, and a full dose after weeks off can act like a sudden escalation. Wharton and colleagues pooled the STEP 1, 2 and 3 trials in Diabetes, Obesity and Metabolism (2022), comparing 2117 people on semaglutide 2.4 mg with 1262 on placebo.

Nausea affected 43.9% of semaglutide users versus 16.1% on placebo, and vomiting 24.5% versus 6.3%. The authors reported that most of these events were mild to moderate (98.1%), transient, and occurred most often during or shortly after dose escalation. Only 4.3% stopped treatment permanently because of them.

The Zepbound label shows the dose side of the same pattern. Nausea was reported by 8% on placebo and by 25%, 29% and 28% on tirzepatide 5, 10 and 15 mg. Vomiting rose from 2% on placebo to 8%, 11% and 13%.

Microdose protocols sit well below these doses, and that is part of their appeal. A lower dose probably means a smaller jolt on restart, but the escalation effect has not been measured at microdoses. If nausea is already a problem, our guide to managing nausea on a GLP-1 microdose covers the practical side.

How do you restart a GLP-1 microdose after two or more missed weeks?

After two or more missed weeks, the safest restart is one planned with the prescriber, usually at a lower dose than before. That is the only restart instruction any of the three labels gives: Wegovy says to reinitiate escalation at a lower dosage after 2 or more consecutive missed doses. The Zepbound and Ozempic missed-dose sections do not set out a restart schedule.

The labeled escalation ladders show what "starting lower" means at standard doses. Wegovy starts at 0.25 mg for weeks 1 through 4 and steps up every 4 weeks to the maintenance dose. The label also allows a 4-week delay in escalation if a dose is not tolerated. Zepbound starts at 2.5 mg for 4 weeks and rises in 2.5 mg steps after at least 4 weeks on each dose.

For someone already on a microdose, the dose may sit at or below the first rung of these ladders, so "restart lower" can mean a smaller step back than it does for someone on full maintenance. How far to step back, and how quickly to climb again, has not been studied for microdose users. That judgement depends on how long the break was, how well the previous dose was tolerated, and why the doses were missed.

The reason for the gap matters too. Doses skipped during vomiting or a fever fall under different advice, covered in our article on sick-day rules for GLP-1 microdosing.

Will missing a dose make you regain weight?

A single missed dose has not been studied as a cause of weight regain, and the drug's long half-life makes a large effect unlikely. The evidence on regain comes from trials that stopped the drug for close to a year, which is a very different situation from a forgotten week.

In STEP 4, published by Rubino and colleagues in JAMA (2021), 803 adults who had reached semaglutide 2.4 mg and lost a mean 10.6% over a 20-week run-in were randomized to continue or switch to placebo. From week 20 to 68, weight changed by -7.9% with continued semaglutide and by +6.9% after the switch to placebo.

SURMOUNT-4, reported by Aronne and colleagues in JAMA (2024), ran the same test with tirzepatide. After a 36-week lead-in with a mean loss of 20.9%, 670 participants were randomized. From week 36 to 88, weight changed by -5.5% on tirzepatide and by 14.0% on placebo. At week 88, 89.5% of those still on tirzepatide had kept at least 80% of their earlier loss, against 16.6% on placebo.

What these trials show is that the effect depends on staying on the drug. They do not show that one late or skipped week undoes progress. The pattern of appetite returning after a longer stop is covered in our article on when the hunger comes back.

How can you avoid missing GLP-1 microdoses?

The most reliable way to avoid missed GLP-1 microdoses is to tie the injection to a fixed weekly event and keep a written record. A phone alarm on the same morning each week, a calendar note that records the dose and site, and a refill reminder set well before the pen or vial runs out cover most of the common failures.

Travel is the other big cause. Moving the injection day before a trip, within the minimum gap each label allows, is usually easier than trying to inject on the road. Our article on travelling with a GLP-1 microdose covers time zones and keeping the medicine cold.

A written log also helps the prescriber if a long gap does happen. Knowing the last dose, the date it was taken and how it was tolerated makes it much easier to choose a sensible restart.

Frequently asked questions

Clinical references

1. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
2. Novo Nordisk. WEGOVY (semaglutide) injection and tablet, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
3. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
4. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022. doi:10.1111/dom.14551
5. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. doi:10.1001/jama.2021.3224
6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. doi:10.1001/jama.2023.24945